Alcoholic liver disease

Pathogenesis, management, and novel targets for therapy

Eric Orman, Gemma Odena, Ramon Bataller

Research output: Contribution to journalReview article

121 Citations (Scopus)

Abstract

Alcohol use is a leading cause of preventable morbidity and mortality worldwide, with much of its negative impact as the result of alcoholic liver disease (ALD). ALD is a broad term that encompasses a spectrum of phenotypes ranging from simple steatosis to steatohepatitis, progressive fibrosis, cirrhosis, and hepatocellular carcinoma. The mechanisms underlying the development of these different disease stages are incompletely understood. Standard treatment of ALD, which includes abstinence, nutritional support, and corticosteroids, has not changed in the last 40 years despite continued poor outcomes. Novel therapies are therefore urgently needed. The development of such therapies has been hindered by inadequate resources for research and unsuitable animal models. However, recent developments in translational research have allowed for identification of new potential targets for therapy. These targets include: (i) CXC chemokines, (ii) IL-22/STAT3, (iii) TNF receptor superfamily, (iv) osteopontin, (v) gut microbiota and lipopolysaccharide (LPS), (vi) endocannabinoids, and (vii) inflammasomes. We review the natural history, risk factors, pathogenesis, and current treatments for ALD. We further discuss the findings of recent translational studies and potential therapeutic targets.

Original languageEnglish (US)
Pages (from-to)77-84
Number of pages8
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume28
Issue numberSUPPL 1
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Alcoholic Liver Diseases
Disease Management
Fibrosis
Therapeutics
Inflammasomes
CXC Chemokines
Endocannabinoids
Osteopontin
Translational Medical Research
Nutritional Support
Tumor Necrosis Factor Receptors
Fatty Liver
Natural History
Lipopolysaccharides
Hepatocellular Carcinoma
Adrenal Cortex Hormones
Animal Models
Alcohols
Morbidity
Phenotype

Keywords

  • Alcoholic liver diseases
  • Fibrosis
  • Inflammation
  • Translational research

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Alcoholic liver disease : Pathogenesis, management, and novel targets for therapy. / Orman, Eric; Odena, Gemma; Bataller, Ramon.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 28, No. SUPPL 1, 2013, p. 77-84.

Research output: Contribution to journalReview article

@article{09672f38068a431c99dcb7d716123967,
title = "Alcoholic liver disease: Pathogenesis, management, and novel targets for therapy",
abstract = "Alcohol use is a leading cause of preventable morbidity and mortality worldwide, with much of its negative impact as the result of alcoholic liver disease (ALD). ALD is a broad term that encompasses a spectrum of phenotypes ranging from simple steatosis to steatohepatitis, progressive fibrosis, cirrhosis, and hepatocellular carcinoma. The mechanisms underlying the development of these different disease stages are incompletely understood. Standard treatment of ALD, which includes abstinence, nutritional support, and corticosteroids, has not changed in the last 40 years despite continued poor outcomes. Novel therapies are therefore urgently needed. The development of such therapies has been hindered by inadequate resources for research and unsuitable animal models. However, recent developments in translational research have allowed for identification of new potential targets for therapy. These targets include: (i) CXC chemokines, (ii) IL-22/STAT3, (iii) TNF receptor superfamily, (iv) osteopontin, (v) gut microbiota and lipopolysaccharide (LPS), (vi) endocannabinoids, and (vii) inflammasomes. We review the natural history, risk factors, pathogenesis, and current treatments for ALD. We further discuss the findings of recent translational studies and potential therapeutic targets.",
keywords = "Alcoholic liver diseases, Fibrosis, Inflammation, Translational research",
author = "Eric Orman and Gemma Odena and Ramon Bataller",
year = "2013",
doi = "10.1111/jgh.12030",
language = "English (US)",
volume = "28",
pages = "77--84",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "SUPPL 1",

}

TY - JOUR

T1 - Alcoholic liver disease

T2 - Pathogenesis, management, and novel targets for therapy

AU - Orman, Eric

AU - Odena, Gemma

AU - Bataller, Ramon

PY - 2013

Y1 - 2013

N2 - Alcohol use is a leading cause of preventable morbidity and mortality worldwide, with much of its negative impact as the result of alcoholic liver disease (ALD). ALD is a broad term that encompasses a spectrum of phenotypes ranging from simple steatosis to steatohepatitis, progressive fibrosis, cirrhosis, and hepatocellular carcinoma. The mechanisms underlying the development of these different disease stages are incompletely understood. Standard treatment of ALD, which includes abstinence, nutritional support, and corticosteroids, has not changed in the last 40 years despite continued poor outcomes. Novel therapies are therefore urgently needed. The development of such therapies has been hindered by inadequate resources for research and unsuitable animal models. However, recent developments in translational research have allowed for identification of new potential targets for therapy. These targets include: (i) CXC chemokines, (ii) IL-22/STAT3, (iii) TNF receptor superfamily, (iv) osteopontin, (v) gut microbiota and lipopolysaccharide (LPS), (vi) endocannabinoids, and (vii) inflammasomes. We review the natural history, risk factors, pathogenesis, and current treatments for ALD. We further discuss the findings of recent translational studies and potential therapeutic targets.

AB - Alcohol use is a leading cause of preventable morbidity and mortality worldwide, with much of its negative impact as the result of alcoholic liver disease (ALD). ALD is a broad term that encompasses a spectrum of phenotypes ranging from simple steatosis to steatohepatitis, progressive fibrosis, cirrhosis, and hepatocellular carcinoma. The mechanisms underlying the development of these different disease stages are incompletely understood. Standard treatment of ALD, which includes abstinence, nutritional support, and corticosteroids, has not changed in the last 40 years despite continued poor outcomes. Novel therapies are therefore urgently needed. The development of such therapies has been hindered by inadequate resources for research and unsuitable animal models. However, recent developments in translational research have allowed for identification of new potential targets for therapy. These targets include: (i) CXC chemokines, (ii) IL-22/STAT3, (iii) TNF receptor superfamily, (iv) osteopontin, (v) gut microbiota and lipopolysaccharide (LPS), (vi) endocannabinoids, and (vii) inflammasomes. We review the natural history, risk factors, pathogenesis, and current treatments for ALD. We further discuss the findings of recent translational studies and potential therapeutic targets.

KW - Alcoholic liver diseases

KW - Fibrosis

KW - Inflammation

KW - Translational research

UR - http://www.scopus.com/inward/record.url?scp=84880414748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880414748&partnerID=8YFLogxK

U2 - 10.1111/jgh.12030

DO - 10.1111/jgh.12030

M3 - Review article

VL - 28

SP - 77

EP - 84

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - SUPPL 1

ER -